Cartier Esham’s Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases
July 30, 2021
BIO regularly publishes reports that help us assess the health of the biopharmaceutical pipeline across different diseases so that we can identify and remove barriers to providing next generation cures and treatments to patients and their families. I will highlight three such analyses with a focus on neurology clinical development programs (pipeline, investment and clinical trial success rates) with the goal of providing helpful insights to this important conversation. Later I will do a deeper dive into Alzheimer’s Disease as an example of the state of innovation for neurodegenerative diseases.
Download Full Comments Below
Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases
Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating…
Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in…
Dear Majority Leader Thune, Minority Leader Schumer, Speaker Johnson, and Minority Leader Jeffries:The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory based non-profit trade associations, each of…
BIO regularly publishes reports that help us assess the health of the biopharmaceutical pipeline across different diseases so that we can identify and remove barriers to providing next generation cures and treatments to patients and their families. I will highlight three such analyses with a focus on neurology clinical development programs (pipeline, investment and clinical trial success rates) with the goal of providing helpful insights to this important conversation. Later I will do a deeper dive into Alzheimer’s Disease as an example of the state of innovation for neurodegenerative diseases.